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19.1
Cells culture in lumbar disc disease 
H.J. Meisel1, T. Ganey2, C. Hohaus1, Y. Minkus1, J. Libera1, O. Josimovic-
Alasevic1, W. Hutton2, 1Germany, 2United States of America 
Low back pain is an extremely common symptom, affecting nearly 
three-quarters of the population sometime in their life. While 90% 
of the population recovers within 3 months, in some patients chronic 
back or leg pain leads to long term physical disability and a reduced 
quality of life. Disc anatomy would be expected to play a pivotal role 
in the underlying pain, yet abnormal spine and disc morphology 
including disc herniation has been described as a normal component 
of an asymptomatic population. Why is it that some patients remain 
asymptomatic, and is it possible to treat patients with degenerative 
change that become symptomatic? Given that disc herniation is 
thought to be an extension of progressive disc degeneration that 
attends the normal aging process, seeking an effective therapy that 
staves disc degeneration has been considered a logical attempt to 
reduce back pain. Previous studies have validated genetic factors, and 
implicated nutrition as relevant to the degenerative process. However, 
the high prevalence across diverse populations suggests that a 
NZSJBEPGVOJEFOUJ¾FEGBDUPSTMJLFMZDPOUSJCVUFUPTJNJMBSTZNQUPNT
As no effective therapies to retard or reverse disc degeneration 
have yet been devised, a variety of surgical procedures have been 
developed to treat disc degeneration and back pain. Unfortunately, 
the procedures currently available fail to offer an outcome that is 
prosthetic and at the same time physiologic. Surgery tends to limit 
motion, and fusion in particular seems to shunt excessive stresses 
to adjacent spinal segments. Equally concerning in selecting fusion 
as an option is the fact that non-unions have been reported in 5-35% 
of patients, and that patients undergoing a repeat fusion for failed 
surgery in the lumbar spine may still have a clinical failure rate as 
high as 40%. The advent of tissue engineering has broadened the 
options for considering treatments that tailor repair to distinct 
anatomy. In particular, the use of cell and gene therapy to endow 
TQFDJ¾D QSPQFSUJFT PS SFQBJS TQFDJ¾D UJTTVFT JT XJEFMZ DPOTJEFSFE
BO FNFSHJOHNPEBMJUZ GPS FGGFDUJOH USFBUNFOU /VNFSPVT TDJFOUJ¾D
studies have provided observations concerning the biochemistry 
and biomechanics of the disc, offering insights and theories into 
structure-function-failure relationships. The most apparent cellular 
and biochemical changes attributable to degeneration include a 
decrease in cell density in the disc that is accompanied by a reduction 
JOTZOUIFTJTPGDBSUJMBHFTQFDJ¾DFYUSBDFMMVMBSNBUSJYDPNQPOFOUTTVDI
as Type II collagen and aggrecan. As the proteoglycan content of the 
disc decreases, the resulting loss of water-binding capacity by the disc 
matrix coupled with a subsequent reduced capacity for dissipating 
spinal forces are thought to lead to disc disease. Collagen plays a key 
load-bearing role in the disc, and changes in its extracellular matrix 
content have been attributed to aging as well as to the pathology of 
degeneration. In normal intervertebral discs, at least seven different 
types of collagen are present (i.e., Types I, II, III, V, VI, IX, and XI), 
BMUIPVHI5ZQFT*BOE**BSFUIFNPTUBCVOEBOU5IFBOVMVT¾CSPTVT
contains more Type I collagen than Type II, whereas the nucleus 
QVMQPTVTJTDPNQPTFENBJOMZPG5ZQF**DPMMBHFO$BMDJ¾DBUJPOPGUIF
vertebral endplates is another factor thought to be relevant to disc 




shortcomings of permeability would be expected to adversely effect 
chondrocyte metabolism. While cells constitute only 1% of the adult 
disc tissue by volume, their role in matrix synthesis and metabolic 
turnover is vital. Most assessments of intervertebral disc failure 
have focused on degenerative, morphologic changes in disc tissue 
morphology that affect the biomechanical performance of the motion 
segment. In this consideration, mechanical failure is little more than 
a corollary of matrix structure, which in turn depends on balanced 
DFMMNFUBCPMJTN GPSFG¾DJFOUNBJOUFOBODFPG UIFEJTDNBUSJY(JWFO
the value of cells to the metabolic health of the disc, one therapeutic 
strategy would be to either replace, regenerate, or augment the 
intervertebral disc cell population, with a goal of correcting matrix 
JOTVG¾DJFODJFTBOESFTUPSJOHOPSNBMTFHNFOUCJPNFDIBOJDT3FDFOU
work has shown that disc aging and degeneration are accompanied 
by a decline in the number of cells in the disc, a change attributable 
to both necrosis and apoptosis. Perhaps a more important outcome 
of this work and that of others has been to demonstrate that disc 
chondrocytes retain an ability to respond to both genetic endowment 
and appropriate in vivo stimulation, and that when returned to the 
disc under controlled conditions integrate with the surrounding 
tissue. With this in mind, we designed a study (using the dog as our 
model) to investigate the hypothesis that 1) repair of the damaged 
disc is technically feasible, 2) autologous cells can be reproducibly 
DVMUVSFEVOEFSEF¾OFEBOEDPOUSPMMFEDPOEJUJPOT
QFSDVUBOFPVT
delivery is possible, and that 4.) disc chondrocytes will integrate with 
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the surrounding tissue, produce the appropriate intervertebral disc 
extracellular matrix, and potentially provide a functional solution to 
disc repair. 
Canine Trial - Experimental Design: The goal of this study was to test 
the hypothesis that restoration of intervertebral disc morphology 
could be achieved by transplantation of cultured autologous 
chondrocytes into the nucleus pulposus. As a natural model of 
degeneration has not been described in a large mammal, this study 
was fashioned after established work demonstrating that 
degeneration can be stimulated by damaging the outer anulus. Under 
institutional guidelines of the Institutional Animal Care and Use 
Committee (IACUC), 18 purpose-bred, 2-year old female dogs, 
weighing between 20-25 Kg, were studied to see whether the 
introduction of cultured autologous disc-derived cells would repair a 
damaged disc and inhibit degenerative changes. Prior to surgery, 
125-ml of blood was obtained from each of the dogs to serve as a 
serum supplement for autologous cell culture. As blood loss was 
JOTJHOJ¾DBOUEVSJOH UIF TVSHJDBM QSPDFEVSF UIJT BQQSPYJNBUF
loss of total blood volume was not considered an additional risk to 
the animals. The dogs were divided into two basic groups; four 
animals receiving autologous cells containing a nuclear marker, the 
other fourteen receiving autologous cells without a nuclear marker. 
Animals were radiographed to establish a baseline for pre-existing 
spine pathology. Under general anesthesia, an approach was made 
to the posterolateral aspect of the canine lumbar spine. Lumbar 
intervertebral discs at three levels (L1/L2, L2/L3, and L3/L4) were 
JEFOUJ¾FE BT TUVEZ MFWFMT GPS UIF QSPDFEVSF BOE EJTD UJTTVF XBT
collected. Approximately 200 mg of tissue was collected from the 
lateral aspect of the anulus, 100 mg of anulus material, and 100 mg of 
nucleus pulposus material. In this study, the L1-L2 intervertebral disc 
had tissue removed but did not receive chondrocyte transplantation, 
the L2-L3 disc was approached but not violated and served as a 
surgical control, and the L3-L4 level had disc material removed and 
received chondrocyte transplantation 12 weeks later. The wound 
sites were closed with resorbable suture and the animals returned to 
their holding area. None of the animals developed problems related 
to the surgery and all regained full function. Twelve weeks after disc 
tissue had been harvested; the autologous disc chondrocyte cell 
cultures were transplanted at L3-L4 on each of the dogs. The 
intervertebral disc between L1-L2 served as the control for untreated 
degeneration. Cells were shipped from Teltow, Germany, overnight at 
4-8 C for transplantation. Animals were anesthetized, placed in right 
MBUFSBMSFDVNCFODFBOEUIF--MFWFMXBTMPDBUFECZ¿VPSPTDPQJD
imaging. As the previous surgeries had been performed from the right 
lateral side, the cultured cells were introduced through the left side of 
the anulus. EuroDisc Randomized Trial The goal of the EuroDISC 
Study was to embrace a representative patient group, examining not 
only the traumatic, less degenerative disc, but also to include patients 
with persistent symptoms that had not responded to conservative 
treatment where an indication for surgical treatment was given. Disc 
IFSOJBUJPO USFBUFE CZ EJTDFDUPNZ SFTVMUT JO B TJHOJ¾DBOU MPTT PG
nucleus material and disc height. Biological restoration with 
interventional cell therapy offers a potential for accentuating disc 
metabolism with an underlying intent to restore spine mechanics. 
Patients having exclusively one level requiring surgical intervention 
were eligible for participation in the trial; patients requiring treatment 
at more than one level were excluded from the study. Prior to their 
participation, all patients were advised of the potential risks and 
signed a letter of consent. No placebo group was committed to this 
study; each patient participating in the clinical trial will undergo 
surgical treatment for their disc prolapse, and the prospective basis 
of cell transplantation will constitute and separate the active 
treatment from the control group. Patients were not blinded to their 
treatment. Randomization was done after the open microdiscectomy. 
Eligibility was limited to patients between 18 and 60 years of age, 
with a body mass index (BMI) below 28. Exclusion criteria for 
participating in the study included sclerotic changes, edema, Modic 
changes of grade II or III, and spondylolisthesis among other accepted 
criteria such as pregnancy, etc. Twenty-eight patients constitute this 
report; 12 patients received cell transplantation following discectomy, 
16 patients were treated by discectomy alone. A single puncture with 
a minimal caliber cannula was used to obtain a precise delivery with 
minimal trauma to the patient and to the anulus. The technique was 
developed with respect to literature that has demonstrated a size-
TQFDJ¾DDPSSFMBUJPOPGBOVMBS JOKVSZ UPEJTDEFHFOFSBUJPO"TJNQMF
minimally-invasive technique was necessary to reduce the wound 
site trauma and effectively support cell injection without further injury 
to the anulus. Cells are transplanted approximately 12 weeks following 
discectomy to assure that the anulus has healed and will contain the 
cells. Using a pressure-volume test prior to the delivery of any 
DIPOESPDZUFTDFMMTDPVMECFQMBDFEXJUIDPO¾EFODFUIBUUIFZXPVME
be retained at the site of delivery. One hundred and twelve patients 
have been enrolled in the EuroDisc Study; the primary criteria follow-
up was intended to occur at 1 year, an interim analysis scheduled at 2 
ZFBSTBOEUIF¾OBMBOBMZTJTXJMMCFDPNQMFUFEBUZFBST5IFQSJNBSZ
clinical evaluation criterion is the Oswestry Low Back Pain Disability 
Questionnaire. Secondary criteria include the SF-36, PROLO, Quebec 
Back Pain Disability Scale, MRI, and X-ray evaluation. Use of the 
Oswestry disability questionairre in clinical trials is recommended by 
the DGOT (Deutsche Gesellschaft für Orthopädie und Traumatologie); 
demonstating acceptable test quality and satisfactory test-retest 
reliability. The Quebec backpain disability scale, another self-rating 
scale, was professionally developed using factor analysis comprising 
with high internal consistency, high item discriminability, and high 
test-retest reliability. Finally, the SF-36, an often used scale to assess 
patients’ general condition and quality of life, and a VAS will be used 
to standardize measureable pain. Interim Analysis - Critical Evaluation 
An interim analysis, made by a cut in January of 2006 to assess 
whether intervention was correlated with positive clinical outcomes, 
forms the basis for this report. Within the analysis, successive 3-
NPOUINPOUINPOUIBOENPOUIBTTFTTNFOUTBSFTUSBUJ¾FE
within the continuum of study. The information within this study 
allows a broad interpretation of the general progress made over 2 
years following a clinical intercession with autologous disc 
DIPOESPDZUFT*OUFSJNBOBMZTJTXBTQFSGPSNFEPOUIF¾STUQBUJFOUT
who reached 24-months follow-up to the autologous disc chondrocyte 
USBOTQMBOUBUJPO	"%$5
5IFTF¾STUQBUJFOUTXFSFSBOEPNJ[FEJO
EJGGFSFOU DFOUFST 'PS EFTDSJQUJWF BOBMZTJT PG FG¾DBDZ UIF UPUBM
sumscore as well as the disability index of the Oswestry Low Back 
Pain Disability Questionaire (OPDQ) and the total sumscore of the 
Quebec Back-Pain Disability Scale (QBPD) were taken into account 
from the initial presurgical presentation through the 2-year follow-up. 
Based on the mean total sumscore as well as the disability index of 
the OPDQ, differences in initial presentations between the control 
group and those receiving autologous cells were not minimal. Surgery 
as an intervention was a positive experience, and as expected 
substantially reduced the patient’s disability and pain. The trend in 
reduction of the total sum score continued to decrease in the patients 
whose treatment was supplemented by cell transplantation, while 
the control group did not sustain continual improvement. 2 years 
following the therapeutic intervention with cells, both the total 
sumscore as well as the disability index of the OPDQ were plainly 
lower in the ADCT group compared with the control. Descriptive 
analyses of the mean total sumscore of the QBPD prior to 
sequestrectomy, prior to ADCT/control, and 3 months after ADCT/
control demonstrated a decrease in mean and median sumscores in 
both groups. Although the mean and median values for both the 
ADCT and the control group decreased between 1 year and 2 years, 
the assessments for the ADCT group were clearly lower. Patient global 
BTTFTTNFOU PG QBJO EFNPOTUSBUFE TPNF¿VDUVBUJPO BMUIPVHICPUI
groups received substantial relief from the surgical intervention. 
However, as patients were tracked over the course of the 2-year 
follow-up, changes emerged that suggest that the ADCT-treated 
patients have a lower assessment of their pain. MRI was used to 
assess the respective disc height along the course of the analyses 
from the date of the sequestrectomy until the 2-year follow-up. In 
addition to the disc height, the content of the liquid component was 
evaluated as a means of assessing matrix content. Results of the 
analysis of the inter-vertebral disc height compared affected (treated 
with surgery, or with surgery and cells) with non-affected adjacent 
segments in the same patients, and also measured the relative 
vertebral heights as a means of assessing patient demographics and 
morphologic variation. Comparison of the mean inter-vertebral disc 
heights and the vertebral heights revealed no differences between 
UIFHSPVQT"OBOBMZTJTPG¿VJEDPOUFOUPGUIFJOUFSWFSUFCSBMEJTDBU
each visit demonstrated that more than 80% of the affected segments 
showed decreased hydration 3-months following surgery. In general, 
the proportion of affected segments with a decreased content of 
liquid decreased over the course of the trial. Of particular interest was 
the outcome at 2 years, where the ADCT treated group showed a 
TVCTUBOUJBMMZ IJHIFS OPSNBMJ[BUJPO BT B HSPVQ  OPSNBM ¿VJE
content compared with only 25% normal content in the control group. 
Perhaps most interesting of all the data to emerge from this study 
comes from inspecting discs either one, or two segments from the 
treated intervertebral disc. Fluid levels at both of these segments 
TIPXFE B TVCTUBOUJBMMZ IJHIFS QFSDFOUBHF PG OPSNBM ¿VJE DPOUFOU
despite the fact that they were away from the surgical intervention 
site. Disc Chondrocyte Transplantation 
Results Radiographs were made of all animals at two-month 
intervals to assure that individual animals selected for tissue 
analysis represented the course of healing for the group rather 
than a disconnected, singular frame of reference. The similarity of 
appearance across the study animals in these periodic assessments 
further suggested that tissue pathology and the regenerative course 
of healing would be both randomized and comparable. MRI Gross 
Pathology Tissue response to surgery was evident in both sagittal 
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and coronal views, with the right side surgical damage apparent 
throughout the study. Spines that were evaluated after 3 months 
demonstrated areas of acute damage, active bone remodeling and 
marrow edema that became less apparent 6 months and 9 months 
after transplantation. Although all levels that had surgical treatment 
XFSF JEFOUJ¾BCMF  NPOUIT BGUFS USBOTQMBOUBUJPO EJGGFSFODFT JO
appearance were evident between the untreated degenerated level 
(L1-L2), the normal intervertebral disc (L2-L3), and the level that 
had received the chondrocyte transplantation (L3-L4). Subchondral 
resolution of the marrow and re-establishment of the vertebral margin 
with the disc of the L3-L4 level was the primary positive change 
associated with time. After 12 months, regeneration of nucleus 
material was slightly better at the level having received the cell 
therapy (L3-L4) in both T1- and T2-weighted images. The differences 
between the two levels were interpreted from the prospective of 
shape of the regenerate material as well as in the central intensity of 
the regenerate matrix. Both experimental levels differed substantially 
from the L2-L3 control level. Healing correlated with the interval of 
time over which the intervertebral discs underwent self-repair or 
repair with the transplanted chondrocytes. In the 3-month animals, 
profound reduction of color of the vertebral bone and marrow were 
BUUSJCVUBCMFUPJO¿BNNBUJPOBOEXPVOEIFBMJOH5IF²GPPUQSJOU³PG
the surgical site was notable at both experimental levels. In the 6-
month animals, the most noticeable change was in the healing of the 
EJTD UIF MPTTPGNBSSPXCMBODIJOH UIF SFEVDUJPO JO JO¿BNNBUJPO
and the widening difference in appearance between the level 
receiving the cells and the level left to heal on its own accord. While 
disc heights were not substantially different at this timepoint, the 
level having not received cells had generated scar tissue rather than 
regenerating normal disc material. Only traces of involvement of the 
vertebral bone were apparent, although the most lateral margin of 
the endplate was still remodeling. In the 9-month animal, differences 
in healing between the intervertebral disc receiving cells (L3-L4) and 
the untreated level (L1-L2) was more obvious. Dense scar tissue had 
developed in place of the more lucent disc material that would be 
expected in normal nucleus pulposus. Although the level receiving 
cells did not demonstrate morphology mirroring nucleus pulposus, a 
bursa like separation could be seen that contained an opaque white 
matrix. Most concerning in this 9-month group of animals was lateral 
involvement of the vertebral margins. The general concept of anulus 
JOKVSZBTTVG¾DJFOUUPDBVTFEJTDEFHFOFSBUJPOIBTCFFOLOPXOGPS
some time. A potential for lateral osteophyte formation resulting 
GSPNTVSHJDBMJOKVSZPGUIFBOVMVTXBTBQQBSFOUJOUIF¿BSJOHPGUIF
disc margin on the side at which surgery had been performed both 
at the L1-L2 and at the L3-L4 levels. Differences in morphology 
SF¿FDUFEUIFTFMFDUJWFPSHBOJ[BUJPOPGUIFUJTTVFTBOEUIFJOUFSGBDF
between disc and the subchondral interface of the vertebral body. 
Intervertebral discs receiving cells (L3-L4) achieved a distinction 
from the bone margins, while the untreated L1-L2 levels developed a 
“fuzzy” interface with the bone. The lateral margins of the vertebral 
bone were involved irrespective of the treatment arm of the study. 
Discussion:
The canine study evaluated whether autologous disc chondrocyte 
transplantation might be an appropriate therapeutic treatment to 
repair disc damage and inhibit degeneration. In this context, several 
important observations emerged. Autologous disc chondrocytes 
were expanded in culture and returned to the disc by a minimally 
JOWBTJWFQSPDFEVSFBGUFSXFFLT6OEFSEF¾OFEDPOEJUJPOTJUXBT
possible to assure phenotype and assess metabolic capacity of the 
cells prior to transplantation. Disc chondrocytes remained viable 
after transplantation as shown by BrdU incorporation and maintained 
a capacity for proliferation after transplantation as depicted by 
histology. Transplanted disc chondrocytes produced an extracellular 
matrix that contained components similar to normal intervertebral 
disc tissue. Positive evidence of proteoglycan content was supported 
by accepted histochemical staining techniques such as Safranin O-
Fast Green. Both Type II and Type I collagens were demonstrated in 
the regenerated intervertebral disc matrix by immunohistochemistry 
following chondrocyte transplantation. There was a statistically 
TJHOJ¾DBOU DPSSFMBUJPO CFUXFFO USBOTQMBOUJOH DFMMT BOE SFUFOUJPO
of disc height that was demonstrated at longer intervals following 
transplantation. Although a morphotypic nucleus pulposus was 
not generated, cells that could appropriately be considered disc 
DIPOESPDZUFT XFSF JEFOUJ¾FE JO UIF JOUFSWFSUFCSBM EJTDT UIBU IBE
received disc chondrocyte transplantation. The observed matrix to cell 
ratio suggested strongly that these cells were elaborating a cartilage 
TQFDJ¾DNBUSJY UIBUXBT BQQSPQSJBUFXJUI SFTQFDU UP CPUI DPMMBHFO
and proteoglycan components. No evidence of necrotic change was 
present, nor were there any active signs of tissue vascularization. 
Absence of bone in the intervertebral space, and the productive 
matrix synthesis suggested that active remodeling and expression 
were guided by the demands of the anatomy, and that cell response 
after transplantation was dependent on both phenotypic identity of 
the cells and the biomechanical cues of the anatomy. Cell viability 
and their capacity for matrix synthesis were particularly encouraging 
outcomes of this study. In the light of a 12-week interval between disc 
tissue sampling and cell transplantation, cells were placed into an 
environment that had fundamentally changed in both composition 
and function. Under the provision of central delivery and pressurized 
containment, the transplanted cells were primed in the vein of the 
nucleus pulposus. The high cell to volume ratio of the transplanted 
cells, the deformable nature of the regional anatomy, and the inherent 
capacity of the cells to respond to new loading regimens all supported 
the vitality of the transplant conditions. Extracellular matrix change, 
biomechanical variation, altered morphology, and cell viability are 
acknowledged steps leading to intervertebral disc degeneration. In 
invigorating the population of vital disc chondrocytes and achieving 
matrix transformation, positive action in addressing the morphology of 
the disc has been demonstrated. The ability to control cell conditions, 
potentially to imbue the cells with additional genetic capacity, and 
the availability of autologous tissue from discectomy procedures 
make this a technology that is available, effective and attractive. 
Interventional surgery for disc herniation is one of the most widely 
used and effective treatments for back pain that emerges within the 
broad scope of disc degeneration. Successful removal of impinging 
tissue offers the individual patient substantial relief for associated 
pain. However, the reduction of tissue involved in the surgical 
procedure anatomically compromises the function of the affected 
disc, and effects a load transfer to adjacent discs. The goal of the 
clinical trial was to evaluate whether ex vivo expansion of autologous 
disc chondrocytes and subsequent percutaneous transplantation 
would positively affect the disc treated, and potentially stabilize 
the spine in general. The principle outcomes of our study were: Disc 
chondrocytes that had been removed as a normal part of discectomy 
could be expanded in culture under GMP conditions and returned to 
the patient after the anulus had been allowed to heal for 12 weeks. 
Disc chondrocyte transplantation could be delivered by percutaneous 
technique. Patients who received autologous disc chondrocyte 
transplantation had greater pain reduction at 2 years compared with 
patients who did not receive cells following their discectomy surgery. 
%JTDT JO QBUJFOUT UIBU SFDFJWFE DFMMT EFNPOTUSBUFE B TJHOJ¾DBOU
EJGGFSFODFBTBHSPVQJOUIF¿VJEDPOUFOUPGUIFJSUSFBUFEEJTDXIFO
compared to control. Adjacent intervertebral discs, both at 1 level or 
2 levels from the intervertebral disc that received the cell therapy 
BMTP EFNPOTUSBUFE B EJGGFSFODF JO ¿VJE DPOUFOU 8IJMF XF XFSF
unable to examine the morphology of the patients who participated 
in the EuroDisc clinical trial, the similarity of the positive patient 
outcomes to those observed in the canine study offers an inviting, 
albeit transitive hint to the success. In the dog study, a hallmark of 
the recovery period was the active bone remodelling of the vertebral 
endplate. Profusely vascularized, laden with stem cells, the biological 
activity was accompanied by a thinning of the vertebral endplate. 
Timing the delivery of the cells in synchrony with the regenerative 
conditions brought about by the discectomy intervention appeared 
to accentuate the metabolic exchange during a particularly critical, 
post-transplantation period. Overriding opinion suggests that end-
plate thickness is seminal to the degenerative process; in this regard 
the reactive endplate modelling and the apparent thinning during 
the surgical recovery period may represent positive and necessary 
conditions of the cell transplantation success. Coupling adequate 
if not enhanced matrix conditions with the symptomatic relief from 
lower back pain affords patients the opportunity to couple dynamic 
stimulation with enhanced biological competence. The results of this 
TUVEZ BSF FODPVSBHJOH GSPN TFWFSBM QFSTQFDUJWFT ¾STU UP UIF GBDU
that the morphologic outcomes mirrored that seen in our pre-clinical 
animal study and second that the pain relief seen in the pilot study 
which served as a basis for this clinical trial was sustained for the 
course of this 2-year interim analysis. This gives cause to the success 
of the cell-based intervention. Critics of autologous disc chondrocyte 
transplantation have cited intervention with cells isolated from 
degenerative matrices as potentially lacking full capacity to restore 
normal conditions. From this 2-year follow-up, it would appear that 
cell transplantation supported pain relief in patients receiving them 
as well as supplemented the morphology of the disc and adjacent 
discs. Because the disc has such a limited intrinsic capacity for 
regeneration, and based on the perceived needs for large amounts of 
proteoglycan and Type II collagen in the regenerating matrix, several 
possible donors for cell-based therapeutics have been considered. 
However, neither in vitro methods for inducing the differentiation of 
stem cells into NP cells, nor the demonstration of clinical application 
has been accomplished. To date, ADCT remains the only cell lineage 
that has been clinically tested and shown to be effective for providing 
long term pain relief and sustaining disc morphology. 
